Low molecular weight heparin: A bridge over troubled water

European Heart Journal

Volumn 23, Issue 15, 2002, Pages 1144-1146

  Verheugt, F W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TIROFIBAN; WARFARIN;

ANGIOPLASTY; ANTICOAGULANT THERAPY; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY THROMBOSIS; EDITORIAL; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REVASCULARIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION;

ANTICOAGULANTS; ASPIRIN; CORONARY ARTERIOSCLEROSIS; DALTEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS; WARFARIN;

EID: 0036700838     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3149     Document Type: Editorial

References (14)

1. White HD, Van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation 1998; 97: 1632-46.
2. Theroux P, Fuster V. Acute coronary syndromes: Unstable angina and non-Q wave myocardial infarction. Circulation 1998; 97: 1195-1206.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
4. Brouwer MA, Verheugt FWA. Oral anticoagulants in acute coronary syndromes. Circulation 2002 in press.
5. Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 1997; 278: 2093-8.
6. FRISC-2 Investigators. Invasive compared with non-invasive treatment of unstable coronary artery disease. Lancet 1999; 354: 708-15.
7. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
8. Boden WE, O'Rourke RA, Crawford MH et al. Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared to a conservative management strategy. N Engl J Med 1998; 338: 1785-92.
9. Husted SE, Wallentin L, Lagerqvist B et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularisation. Eur Heart J 2002; 23: 1213-8.
10. Verheugt FWA, Brouwer MA, Ezekowitz MD, Fiore L, Fuster V. Risks versus benefit of oral anticoagulation on top of aspirin following unstable angina or myocardial infarction: A meta-analysis (abstr). Circulation 2001; 104 (Suppl II): 84.
11. Remmen JJ, Verheugt FWA. Hotline sessions of the 23rd European Congress of Cardiology. Eur Heart J 2001; 22: 2033-7.
12. Cromheecke ME, Levi M, Colly LP et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: A randomised cross-over comparison. Lancet 2000; 356: 97-102.
13. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-33.
14. CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.